Form 4: Cytek Biosciences CFO William McCombe Reports Stock Transactions

William D. McCombe, CFO of Cytek Biosciences, reports the vesting and subsequent tax withholding related to restricted stock units.

Summary

• On May 19, 2025, William D. McCombe, the Chief Financial Officer of Cytek Biosciences, engaged in transactions involving the company's common stock.
• These transactions included the vesting of 25,283 and 8,700 restricted stock units (RSUs) and the subsequent withholding of 9,848 and 3,389 shares, respectively, to cover tax obligations.
• Following these transactions, McCombe directly owns 20,746 shares of Cytek Biosciences common stock and 275,965 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to attract and retain talent.
• Vesting schedules for restricted stock units typically range from three to five years, aligning with industry norms.
• Tax withholding practices related to RSU vesting are standardized across publicly traded companies.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and insider transactions.
• Employees holding RSUs will be affected by the vesting schedules and tax implications.

Key Dates

Keywords

Cytek Biosciences, CTKB, William D. McCombe, CFO, Form 4, Restricted Stock Units, RSU, Insider Trading, Beneficial Ownership, Stock Transactions